Glomerulonephritis, IGA: Clinical Trials

3 trials for Glomerulonephritis, IGA, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 3
Phase 21Terminated 1

Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
OMS721, Vehicle (D5W or saline) - IgA Nephropathy
Phase 3TerminatedOmeros Corporation3602018-04-052025-12-09
Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Plasma Exchange (PE), Methylprednisolone pulse - Glomerulonephritis, IGA, Kidney Diseases
Phase 2 / Phase 3TerminatedPeking University First Hospital102016-03-012021-10-08
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
Mycophenolate Mofetil (MMF), MMF Placebo, ACEi - IgA Nephropathy
Phase 3TerminatedSt. Joseph's Hospital and Medical Center, Phoenix1842002-01-012016-03-07

Narrower conditions

Proteinuria (2)  ·  Acute Kidney Injury (1)  ·  Kidney Diseases (1)  ·  Renal Insufficiency, Chronic (1)

Broader conditions

Autoimmune Diseases (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Glomerulonephritis (3)  ·  Immune System Diseases (3)  ·  Male Urogenital Diseases (3)  ·  Nephritis (3)  ·  Urogenital Diseases (3)  ·  Urologic Diseases (3)  ·  Kidney Diseases (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Renal Insufficiency (2)  ·  Signs and Symptoms (2)  ·  Urination Disorders (2)  ·  Urological Manifestations (2)

Interventions

Angiotensin-Converting Enzyme Inhibitors (1)  ·  Mycophenolic Acid (1)  ·  Plasma Exchange (1)  ·  Plasmapheresis (1)  ·  Sodium Chloride (1)  ·  narsoplimab (1)

Sponsors

Omeros Corporation (1)  ·  Peking University First Hospital (1)  ·  St. Joseph's Hospital and Medical Center, Phoenix (1)

Countries

United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)  ·  Lithuania (1)  ·  Poland (1)

Top investigators

Hong Zhang, MD, PHD (1)  ·  Ronald J Hogg, M.D. (1)

Results publications

PMID 38299639, PMID 35675911, PMID 37772889, PMID 38864363